Givinostat clinical trials
Also written ITF2357.
Includes 1 study of Givinostat hydrochloride.
How each study uses givinostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the givinostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Mar 2024 · DUVYZAT · NDA 217865 (FDA, Drugs@FDA)
- European Union
- 6 Jun 2025 · Duvyzat · EMEA/H/C/006079 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 24 · Other 1
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of HDAC inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test givinostat.
- Dec 2026Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsPhase 2 · Italfarmaco
Studies
Open first, then newest update. How each study uses givinostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyRecruitingPhase 3ItalfarmacoNCT05933057Written as Givinostat
- Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraRecruitingPhase 3ItalfarmacoNCT06093672Written as Givinostat
- Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability StudyRecruitingPhase 2/3ItalfarmacoNCT03373968Written as Givinostat
- Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldRecruitingPhase 2ItalfarmacoNCT06769633Written as Givinostat Hydrochloride
- Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic FunctionCompletedPhase 1ItalfarmacoNCT06736223Written as ITF2357
- Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsActive, not recruitingPhase 2ItalfarmacoNCT01761968Written as givinostat
- Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)CompletedPhase 1ItalfarmacoNCT05860114Written as Givinostat
- Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp ActivityCompletedPhase 1ItalfarmacoNCT05492318Written as Givinostat 10 mg/mL
- Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular DystrophyCompletedPhase 2ItalfarmacoNCT03238235Written as Givinostat
- The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)CompletedPhase 1ItalfarmacoNCT05845567Written as Givinostat
- Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC IntervalCompletedPhase 1ItalfarmacoNCT04821063Written as ITF2357 10 mg/mL
- A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMDCompletedPhase 1/2ItalfarmacoNCT01761292Written as Givinostat
- Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's DiseaseTerminatedPhase 1/2ItalfarmacoNCT00792740Written as ITF2357
- Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular DystrophyCompletedPhase 3ItalfarmacoNCT02851797Written as givinostat
- Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple MyelomaTerminatedPhase 2ItalfarmacoNCT00792506Written as ITF2357
- phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma PatientsTerminatedPhase 1/2ItalfarmacoNCT00496431Written as histone deacetylase inhibitor (ITF2357)
- Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic LeukemiaTerminatedPhase 2ItalfarmacoNCT00792831Written as ITF2357
- Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's LymphomaCompletedPhase 1/2ItalfarmacoNCT00792467Written as ITF2357
- Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic ArthritisCompletedPhase 2ItalfarmacoNCT00570661Written as ITF2357
- Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic ArthritisTerminatedNot applicableItalfarmacoNCT01557452Written as Givinostat
Codes
What other systems call givinostat · ClinicalTrials.gg INT015099
- MeSH (NLM) C575255givinostatOne source NLM
- UNII (FDA) 5P60F84FBHGIVINOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q426257givinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71716GivinostatOne source FDA
- DrugBank DB12645One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C575255 | givinostat | One source NLM |
| UNII (FDA) | 5P60F84FBH | GIVINOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q426257 | givinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71716 | Givinostat | One source FDA |
| DrugBank | DB12645 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.